Sugi Predict

Sugi Predict / Compounds / SCHEMBL18667995

SCHEMBL18667995

SCHEMBL18667995

c1ccc(-c2nc(-c3ccccc3)nc(-n3c4c5ccccc5ccc4c4c5ccccc5c5ccccc5c43)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ HPRT1 P00492 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ HSD17B10 Q99714 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ THRB P10828 1/20 0.34
▸ TDP1 Q9NUW8 3/20 0.33
▸ ATM Q13315 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19844122 0.97 MAPT (0.36) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL12691002 0.94 NPC1 (0.37) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL19844121 0.92 MEN1 (0.38) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL25899051 0.91 MAPT (0.44) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL12691004 0.90 EGFR (0.32) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL21432049 0.89 LMNA (0.39) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL12691497 0.89 NPC1 (0.39) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL18668011 0.89 MAPT (0.39) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL18668014 0.88 MAPT (0.38) MAPTSMN1; SMN2LMNANPC1RECQL
SCHEMBL12691210 0.88 NPC1 (0.35) MAPTSMN1; SMN2LMNANPC1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421721-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2019-09-24 — — US disclosed
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2018-02-08 — — US disclosed
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2018-02-08 — — US disclosed
WO-2017047992-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2017-03-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421721-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 MAPT 1166/4885SMN1; SMN2 4259/4885LMNA 3641/4885
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 MAPT 1166/4885SMN1; SMN2 4259/4885LMNA 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.